Skip to content
Dosage GuideResearch Reference

Daptomycin Dosage

Research-based dosing protocols, timing guidance, and reconstitution reference for Daptomycin. All information is for educational purposes only.

Quick Answer

Daptomycin is administered intravenously, typically at 4–6 mg/kg once daily for most infections. Higher doses (8–12 mg/kg) may be used for more severe or difficult-to-treat infections like endocarditis or bacteremia. Dosage adjustments are required for patients with renal impairment. Treatment duration varies based on the infection type and severity.

→ Daptomycin Benefits→ Daptomycin Side Effects→ Full Daptomycin Profile
Table of Contents

Standard Dosage Range

Research dosing range: 4–12 mg/kg once daily, intravenously

Educational reference only

These dosage ranges are derived from preclinical research and community protocols. No human clinical dose-ranging trials have established therapeutic doses for most research peptides. Always consult a qualified healthcare provider before starting any peptide protocol.

Dosage by Use Case

Complicated Skin and Soft Tissue Infections (cSSSTI)

4 mg/kgOnce daily
Duration

7–14 days

Administered intravenously. Duration depends on infection severity.

Staphylococcus aureus Bacteremia (SAB), including MRSA

6 mg/kgOnce daily
Duration

14+ days

Administered intravenously. Higher doses (8-12 mg/kg) may be considered for persistent bacteremia or endocarditis.

Right-Sided Infective Endocarditis (RIE)

6 mg/kgOnce daily
Duration

14+ days

Administered intravenously. Higher doses (8-12 mg/kg) are often used, and consultation with an infectious disease specialist is recommended.

Vancomycin-Resistant Enterococcus (VRE) Infections

8-10 mg/kgOnce daily
Duration

Variable, based on infection site and severity

Administered intravenously. Dosage should be individualized based on renal function and infection characteristics.

Osteomyelitis

6 mg/kgOnce daily
Duration

4-6 weeks

Administered intravenously. Duration may be longer depending on the severity and response to treatment.

Timing & Frequency

Daptomycin is administered intravenously over 30 minutes. It is typically given at the same time each day to maintain consistent drug levels.

Cycle Guidance

Daptomycin treatment duration is determined by the type and severity of infection. Prolonged use may increase the risk of adverse effects, including muscle toxicity and eosinophilic pneumonia. Monitor renal function and CPK levels regularly during treatment.

Reconstitution Reference

Quick reference for reconstituting Daptomycin. For custom vial sizes and concentrations, use the Reconstitution Calculator.

Common Vial SizeTypically 500 mg per vial
BAC Water Volume10 mL sterile water or 0.9% sodium chloride
Concentration & Draw50 mg/mL
StorageReconstituted solution should be used immediately or refrigerated for up to 24 hours.
StabilityLyophilized powder is stable at room temperature. Reconstituted solution is stable for up to 24 hours refrigerated.
Use the Reconstitution Calculator → for precise injection volumes based on your exact vial size, water volume, and desired dose.

Frequently Asked Questions

What is the usual dose of daptomycin for MRSA bacteremia?
The usual dose of daptomycin for MRSA bacteremia is 6 mg/kg once daily, administered intravenously. Higher doses (8-12 mg/kg) may be used for persistent bacteremia or endocarditis.
How is daptomycin administered?
Daptomycin is administered intravenously over 30 minutes.
What monitoring is required during daptomycin therapy?
CPK levels should be monitored weekly (more frequently if the patient is at higher risk for myopathy) to assess for muscle toxicity. Renal function should also be monitored due to potential nephrotoxicity.
Can daptomycin be used for pneumonia?
No, daptomycin should not be used for pneumonia because it is inactivated by pulmonary surfactant.
What are the potential side effects of daptomycin?
Common side effects of daptomycin include nausea, vomiting, diarrhea, injection site reactions, and elevated CPK levels. More serious side effects include myopathy, rhabdomyolysis, eosinophilic pneumonia, and hypersensitivity reactions.

Last updated: 2026-02-19